AR114421A1 - Piperidinil-3-(ariloxi)-propanamidas y propanoatos - Google Patents

Piperidinil-3-(ariloxi)-propanamidas y propanoatos

Info

Publication number
AR114421A1
AR114421A1 ARP190100507A ARP190100507A AR114421A1 AR 114421 A1 AR114421 A1 AR 114421A1 AR P190100507 A ARP190100507 A AR P190100507A AR P190100507 A ARP190100507 A AR P190100507A AR 114421 A1 AR114421 A1 AR 114421A1
Authority
AR
Argentina
Prior art keywords
halo
independently selected
alkyl
substituted
optional substituents
Prior art date
Application number
ARP190100507A
Other languages
English (en)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR114421A1 publication Critical patent/AR114421A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Abstract

Se describen compuestos de fórmula (1), estereoisómeros de estos, y sales farmacéuticamente aceptables de estos, donde L, r, s, R⁵, R⁶, R⁷, R⁹, R¹⁰, R¹¹, R¹², X¹, X², X³, X⁴, X¹³, y X¹⁴ se definen en la memoria descriptiva. Esta descripción también se refiere a materiales y métodos para preparar compuestos de fórmula (1), a composiciones farmacéuticas que los contienen, y a su uso para tratar enfermedades, trastornos y afecciones asociados con SSTR4. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable este donde: X¹ se selecciona de N y CR¹; X² se selecciona de N y CR²; X³ se selecciona de N y CR³; y X⁴ se selecciona de N y CR⁴, con la condición de que no más de dos de X¹, X², X³, y X⁴ sean N; X¹³ es NR¹³ y X¹⁴ es CR¹⁵R¹⁶ o X¹³ es CH₂ y X¹⁴ es NR¹⁴; L se selecciona de NR⁸ y O; r se selecciona de 0 y 1; s se selecciona de 0 y 1; R¹, R² y R³ se seleccionan independientemente de (a) hidrógeno, halo, hidroxi y ciano; y (b) alquilo C₁₋₄, cicloalquilo C₃₋₆ y alcoxi C₁₋₄, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; R⁴ se selecciona de (a) hidrógeno, halo, hidroxi y ciano; y (b) alquilo C₁₋₄, cicloalquilo C₃₋₆ y alcoxi C₁₋₄, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; R⁵ se selecciona de (a) hidrógeno, halo, hidroxi y ciano; y (b) alquilo C₁₋₄, cicloalquilo C₃₋₆ y alcoxi C₁₋₄, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo, oxo y fenilo que está sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; o R⁴ y R⁵, junto con el átomo de carbono al que están unidos, forman un ciclopent-1-en-1,2-diilo o un furan-2,3-diilo; cada R⁶ y R⁷ se selecciona independientemente halo y alquilo C₁₋₃, o R⁶ y R⁷, junto con el átomo de carbono al que están unidos, forman un cicloalcan-C₃₋₄-1,1-diilo; R⁸ se selecciona de H y alquilo C₁₋₄; R⁹ y R¹⁰ se seleccionan cada uno independientemente de (a) hidrógeno, halo, hidroxi y ciano; (b) alquilo C₁₋₄, cicloalquilo C₃₋₆ y alcoxi C₁₋₄, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; y (c) fenilo y heteroarilo C₁₋₅, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo, alquilo C₁₋₄ y alcoxi C₁₋₄, donde el sustituyente de C₁₋₅ heteroarilo es un anillo monocíclico con 5 a 6 miembros del anillo donde 1 a 4 miembros del anillo son heteroátomos, cada uno de los heteroátomos se selecciona independientemente de N, O y S, con la condición de que no más de uno de los miembros del anillo sea O ó S y donde cada uno de los sustituyentes opcionales alquilo C₁₋₄ y alcoxi C₁₋₄ de fenilo y heteroarilo C₁₋₅ está sustituido independientemente con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; o R⁹ y R¹⁰, junto con el átomo de carbono al que están unidos, forman un grupo cicloalcan-C₃₋₄-1,1-diilo; R¹¹ y R¹² se seleccionan cada uno independientemente de (a) hidrógeno, halo, hidroxi y ciano; y (b) alquilo C₁₋₄, cicloalquilo C₃₋₆ y alcoxi C₁₋₄, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; o R¹¹ y R¹², junto con el átomo de carbono al que están unidos, forman un grupo cicloalcan-C₃₋₄-1,1-diilo; R¹³ y R¹⁴ se seleccionan cada uno independientemente de (a) hidrógeno, y (b) alquilo C₁₋₄, que está sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de ciano, oxo y fenilo que está sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; y R¹⁵ y R¹⁶ se seleccionan cada uno independientemente de (a) hidrógeno, halo, hidroxi y ciano; y (b) alquilo C₁₋₄, cicloalquilo C₃₋₆ y alcoxi C₁₋₄, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; o R¹⁵ y R¹⁶, junto con el átomo de carbono al que están unidos, forman un grupo cicloalcan-C₃₋₄-1,1-diilo.
ARP190100507A 2018-03-01 2019-02-28 Piperidinil-3-(ariloxi)-propanamidas y propanoatos AR114421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862637295P 2018-03-01 2018-03-01

Publications (1)

Publication Number Publication Date
AR114421A1 true AR114421A1 (es) 2020-09-02

Family

ID=65763866

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100507A AR114421A1 (es) 2018-03-01 2019-02-28 Piperidinil-3-(ariloxi)-propanamidas y propanoatos

Country Status (20)

Country Link
US (2) US11045457B2 (es)
EP (1) EP3759094A1 (es)
JP (2) JP7297776B2 (es)
KR (1) KR20200138245A (es)
CN (1) CN112236423B (es)
AR (1) AR114421A1 (es)
AU (1) AU2019228568A1 (es)
BR (1) BR112020017644A2 (es)
CA (1) CA3092450A1 (es)
CL (1) CL2020002257A1 (es)
EA (1) EA202092054A1 (es)
EC (1) ECSP20062464A (es)
IL (1) IL276998B2 (es)
MX (1) MX2020009062A (es)
PE (1) PE20211313A1 (es)
PH (1) PH12020551359A1 (es)
SG (1) SG11202008398XA (es)
UA (1) UA126829C2 (es)
WO (1) WO2019169153A1 (es)
ZA (1) ZA202005438B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202008398XA (en) * 2018-03-01 2020-09-29 Takeda Pharmaceuticals Co Piperidinyl-3-(aryloxy)propanamides and propanoates
GB201901559D0 (en) * 2019-02-05 2019-03-27 Syngenta Crop Protection Ag Herbicidal compositions
WO2021143680A1 (zh) 2020-01-16 2021-07-22 浙江海正药业股份有限公司 杂芳基类衍生物及其制备方法和用途
AR121682A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
TW202146403A (zh) * 2020-05-21 2021-12-16 大陸商廣州費米子科技有限責任公司 含氮飽和雜環化合物及其製備方法、藥物組合物和應用
BR112023003328A2 (pt) * 2020-08-24 2023-03-21 Hua Medicine Shanghai Ltd Preparação de composto acrilato substituído
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023187677A1 (en) * 2022-03-30 2023-10-05 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
CN1960970A (zh) * 2004-05-28 2007-05-09 田边制药株式会社 作为cb1受体的拮抗剂的吡咯烷衍生物
JP4943826B2 (ja) 2005-11-25 2012-05-30 田辺三菱製薬株式会社 医薬組成物
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
EP2280966A1 (en) 2008-03-14 2011-02-09 Exelixis, Inc. Azabicyclo [3.2.1]octyl derivatives as 11 beta-hsd1 modulators
WO2015037716A1 (ja) * 2013-09-12 2015-03-19 住友化学株式会社 含窒素飽和複素環化合物
US10071974B2 (en) 2014-11-14 2018-09-11 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists
JP2015037716A (ja) 2014-11-27 2015-02-26 株式会社大一商会 遊技機
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
SG11202008398XA (en) * 2018-03-01 2020-09-29 Takeda Pharmaceuticals Co Piperidinyl-3-(aryloxy)propanamides and propanoates

Also Published As

Publication number Publication date
CN112236423B (zh) 2024-02-06
KR20200138245A (ko) 2020-12-09
ECSP20062464A (es) 2020-12-31
AU2019228568A1 (en) 2020-09-24
ZA202005438B (en) 2023-02-22
US11045457B2 (en) 2021-06-29
CL2020002257A1 (es) 2021-01-29
IL276998A (en) 2020-10-29
SG11202008398XA (en) 2020-09-29
JP2023134444A (ja) 2023-09-27
MX2020009062A (es) 2020-10-12
JP2021515004A (ja) 2021-06-17
TW202000659A (zh) 2020-01-01
BR112020017644A2 (pt) 2021-01-19
IL276998B1 (en) 2023-10-01
JP7297776B2 (ja) 2023-06-26
EA202092054A1 (ru) 2021-01-22
EP3759094A1 (en) 2021-01-06
PH12020551359A1 (en) 2021-08-23
CA3092450A1 (en) 2019-09-06
CN112236423A (zh) 2021-01-15
PE20211313A1 (es) 2021-07-22
IL276998B2 (en) 2024-02-01
US20200061041A1 (en) 2020-02-27
UA126829C2 (uk) 2023-02-08
WO2019169153A1 (en) 2019-09-06
US20230021834A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
AR114421A1 (es) Piperidinil-3-(ariloxi)-propanamidas y propanoatos
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR111284A1 (es) Agonistas del receptor farnesoide x y usos de los mismos
AR088293A1 (es) Inhibidores de proteina cinasa
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR090834A1 (es) Inhibidores de la agregacion plaquetaria
AR121078A1 (es) Derivados de arilamida con actividad antitumoral
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR114369A1 (es) Dinucleótidos cíclicos como agentes antineoplásicos
AR112804A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR105392A1 (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
AR106138A1 (es) Compuestos y métodos para inhibir jak
AR114679A1 (es) Compuestos heterocíclicos fungicidas
AR117900A1 (es) Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b
AR120246A1 (es) Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1
AR105460A1 (es) Derivados sustituidos de 2-pirimidina furano / tienocicloalquilamino y su uso para el control del crecimiento de plantas no deseables
AR096424A1 (es) Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
AR113227A1 (es) Compuestos y composiciones para inducir condrogénesis
AR121573A1 (es) Moduladores de nlrp3